KR101507188B1 - 펩티드 티로시나제 억제제 및 그의 용도 - Google Patents

펩티드 티로시나제 억제제 및 그의 용도 Download PDF

Info

Publication number
KR101507188B1
KR101507188B1 KR1020107001773A KR20107001773A KR101507188B1 KR 101507188 B1 KR101507188 B1 KR 101507188B1 KR 1020107001773 A KR1020107001773 A KR 1020107001773A KR 20107001773 A KR20107001773 A KR 20107001773A KR 101507188 B1 KR101507188 B1 KR 101507188B1
Authority
KR
South Korea
Prior art keywords
peptide
tyrosinase
peptides
formulation
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107001773A
Other languages
English (en)
Korean (ko)
Other versions
KR20100039861A (ko
Inventor
바실 엠. 한타쉬
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20100039861A publication Critical patent/KR20100039861A/ko
Application granted granted Critical
Publication of KR101507188B1 publication Critical patent/KR101507188B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020107001773A 2007-06-27 2008-06-25 펩티드 티로시나제 억제제 및 그의 용도 Expired - Fee Related KR101507188B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93733107P 2007-06-27 2007-06-27
US60/937,331 2007-06-27
PCT/US2008/068186 WO2009003037A1 (en) 2007-06-27 2008-06-25 Peptide tyrosinase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
KR20100039861A KR20100039861A (ko) 2010-04-16
KR101507188B1 true KR101507188B1 (ko) 2015-03-30

Family

ID=40186023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107001773A Expired - Fee Related KR101507188B1 (ko) 2007-06-27 2008-06-25 펩티드 티로시나제 억제제 및 그의 용도

Country Status (7)

Country Link
US (2) US8026208B2 (enExample)
EP (1) EP2180897B1 (enExample)
JP (2) JP5568008B2 (enExample)
KR (1) KR101507188B1 (enExample)
CN (2) CN103864892A (enExample)
CA (1) CA2728140C (enExample)
WO (1) WO2009003037A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641591B1 (en) 1999-08-26 2003-11-04 John H. Shadduck Instruments and techniques for controlled removal of epidermal layers
US8048089B2 (en) 2005-12-30 2011-11-01 Edge Systems Corporation Apparatus and methods for treating the skin
US10172644B2 (en) 2006-03-29 2019-01-08 Edge Systems Llc Devices, systems and methods for treating the skin
US9566088B2 (en) 2006-03-29 2017-02-14 Edge Systems Llc Devices, systems and methods for treating the skin
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
JP5568008B2 (ja) * 2007-06-27 2014-08-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ペプチドチロシナーゼインヒビターおよびその使用
WO2009088884A1 (en) * 2008-01-04 2009-07-16 Edge Systems Corporation Apparatus and method for treating the skin
US9056193B2 (en) * 2008-01-29 2015-06-16 Edge Systems Llc Apparatus and method for treating the skin
WO2011006009A1 (en) 2009-07-08 2011-01-13 Edge Systems Corporation Devices, systems and methods for treating the skin using time-release substances
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
US9067084B2 (en) 2010-03-31 2015-06-30 Agency For Science, Technology And Research Amphiphilic linear peptide/peptoid and hydrogel comprising the same
WO2011154640A2 (fr) * 2010-06-11 2011-12-15 Galderma Research & Development Modulateurs de trmp1, mmp2, mia ou ptgs1 dans le traitement du melasma
WO2011154639A2 (fr) * 2010-06-11 2011-12-15 Galderma Research & Development Modulateurs de edn3 et/ou ednrb dans le traitement du melasma
WO2012154959A1 (en) * 2011-05-11 2012-11-15 Elixir Institute Of Regenerative Medicine Peptide tyrosinase inhibitors and uses thereof
JP6026765B2 (ja) * 2012-04-24 2016-11-16 花王株式会社 チロシナーゼ阻害剤
CN105102469A (zh) * 2013-01-28 2015-11-25 新加坡科技研究局 交联的肽水凝胶
ES2936988T3 (es) 2013-03-15 2023-03-23 Hydrafacial Llc Dispositivos y sistemas para el tratamiento de la piel
US10238812B2 (en) 2013-03-15 2019-03-26 Edge Systems Llc Skin treatment systems and methods using needles
US10179229B2 (en) 2014-12-23 2019-01-15 Edge Systems Llc Devices and methods for treating the skin using a porous member
WO2016106396A1 (en) 2014-12-23 2016-06-30 Edge Systems Llc Devices and methods for treating the skin using a rollerball or a wicking member
US11241357B2 (en) 2015-07-08 2022-02-08 Edge Systems Llc Devices, systems and methods for promoting hair growth
KR101895906B1 (ko) * 2016-07-07 2018-10-04 주식회사 한국화장품제조 펩타이드 리포좀을 포함하는 스틱형 화장료 조성물
US11045493B2 (en) 2016-07-11 2021-06-29 The Regents Of The University Of California Synthetic melanin nanoparticles and uses thereof
BR112019005069A2 (pt) * 2016-09-15 2019-06-04 Dsm Ip Assets B.V. compostos inovadores
CA3082262A1 (en) 2017-11-14 2019-05-23 Unilever Plc Peptides for increasing melanin in melanocytes
EA202091390A1 (ru) 2017-12-06 2020-09-04 Юнилевер Н.В. Композиция для потемнения кожи
CN109180785B (zh) * 2018-11-08 2021-08-20 中国科学院上海应用物理研究所 一种具有抑制黑色素生成和抗紫外线损伤作用的美白还原多肽及其应用
US12441890B2 (en) 2019-10-30 2025-10-14 Northwestern University Selenium-containing analogues of pheomelanin and related materials and methods of making
US11291474B2 (en) 2020-01-06 2022-04-05 Ed F. Nicolas Skin treatment tool applicator tip
WO2021163701A1 (en) * 2020-02-13 2021-08-19 Escape Therapeutics, Inc. Melanoma therapeutics
KR102506020B1 (ko) * 2020-11-27 2023-03-06 웰펩 주식회사 항산화 활성 및 티로시나제 저해활성을 갖는 펩타이드 및 이를 포함하는 조성물
USD1065551S1 (en) 2021-09-10 2025-03-04 Hydrafacial Llc Skin treatment device
USD1016615S1 (en) 2021-09-10 2024-03-05 Hydrafacial Llc Container for a skin treatment device
USD1042807S1 (en) 2021-10-11 2024-09-17 Hydrafacial Llc Skin treatment tip
US12377036B2 (en) 2022-06-21 2025-08-05 Northwestern University Melanin hair dye with thickeners
USD1084369S1 (en) 2023-02-10 2025-07-15 Hydrafacial Llc Skin treatment tip
CN117106015B (zh) * 2023-09-01 2024-04-26 海南大学 一种椰子源活性肽及其应用
CN117106016A (zh) * 2023-09-01 2023-11-24 海南大学 阿胶源酪氨酸酶抑制肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US20020142392A1 (en) 1992-08-21 2002-10-03 Wa Pharm Ab Human melanocyte stimulating hormone receptor polypeptide and DNA
US6602856B1 (en) * 1995-01-17 2003-08-05 J. Mark Quillan Antagonists of alpha-melanocyte stimulating hormone and methods based thereon

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US3978427A (en) 1973-06-15 1976-08-31 American Optical Corporation Erbium laser device having non-masking laser rod holders
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0068693A3 (en) * 1981-06-16 1983-07-20 Genentech, Inc. Production of foot and mouth disease vaccine from microbially expressed antigens
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
EP0389950A1 (en) 1989-03-23 1990-10-03 Lion Corporation Melanocyte-stimulating hormone inhibitor and external preparation containing the same
US5773291A (en) 1989-04-26 1998-06-30 Sloan-Kettering Institute For Cancer Research Non-melanotytic mammalian cell constitutively expressing biologically active human tyrosinase and use thereof
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
AU1194092A (en) 1991-02-06 1992-09-07 Georgetown University Receptor blocking peptides of fibroblast growth factor receptor
US5256766A (en) * 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US5670483A (en) * 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5455228A (en) 1993-07-02 1995-10-03 The Research Foundation Of State University Of New York Peptidase resistant thrombin receptor peptide ligand
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
US5589460A (en) 1994-05-04 1996-12-31 Innapharma, Inc. Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
CN1179105A (zh) * 1995-01-17 1998-04-15 小马克·奎伦 α－促黑激素拮抗剂及相关方法
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
AU5638096A (en) * 1995-06-07 1996-12-30 Clarion Pharmaceuticals, Inc. Non-biological patch for hemostasis
AU723585B2 (en) 1996-03-28 2000-08-31 Trustees Of Boston University Methods of modulating melanin synthesis
US6143723A (en) 1996-05-20 2000-11-07 Ramaiah; Abburi Pigmentory agent
US6165982A (en) 1996-11-08 2000-12-26 Seiren Co., Ltd. Use of sericin as antioxidants and tyrosinase inhibitors
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
US6368877B1 (en) * 1997-06-25 2002-04-09 Massachusetts Institute Of Technology Self-assembling peptide surfaces for cell patterning and interactions
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US20020034772A1 (en) 1999-06-29 2002-03-21 Orlow Seth J. Methods and compositions that affect melanogenesis
US7083781B2 (en) 1999-08-19 2006-08-01 Lavipharm S.A. Film forming polymers, methods of use, and devices and applications thereof
JP2004501166A (ja) 2000-06-16 2004-01-15 ハーキュリーズ・インコーポレーテッド 化学修飾ペプチド、組成物、並びに製造方法および使用
ATE419333T1 (de) * 2001-02-06 2009-01-15 Massachusetts Inst Technology Peptidgerüstverkapselung von gewebszellen und verwendungen davon
US7449180B2 (en) * 2001-02-06 2008-11-11 John Kisiday Macroscopic scaffold containing amphiphilic peptides encapsulating cells
US20020182237A1 (en) 2001-03-22 2002-12-05 The Procter & Gamble Company Skin care compositions containing a sugar amine
US20020192738A1 (en) 2001-04-27 2002-12-19 Janice Brissette Tyrosinase assay
US7658742B2 (en) 2001-11-21 2010-02-09 Envy Medical, Inc. Skin treatment system and method of use
US6695853B2 (en) 2001-11-21 2004-02-24 Emed, Inc. Microdermabrasion system and method of use
US6649150B2 (en) 2002-04-11 2003-11-18 Em Industries Skin-lightening
US7025957B2 (en) 2002-09-06 2006-04-11 Desert Whale Jojoba Company Composition and method to whiten skin
US7125572B2 (en) 2004-05-14 2006-10-24 Kaoder Industry Company, Ltd. Tyrosinase inhibitor extract
WO2007001868A1 (en) 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
JP4742365B2 (ja) 2005-10-04 2011-08-10 独立行政法人産業技術総合研究所 チロシナーゼ阻害剤、美白剤および美白外用剤
JP5568008B2 (ja) * 2007-06-27 2014-08-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ペプチドチロシナーゼインヒビターおよびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142392A1 (en) 1992-08-21 2002-10-03 Wa Pharm Ab Human melanocyte stimulating hormone receptor polypeptide and DNA
US6602856B1 (en) * 1995-01-17 2003-08-05 J. Mark Quillan Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders

Also Published As

Publication number Publication date
CN101795703A (zh) 2010-08-04
CA2728140A1 (en) 2008-12-31
US20090099093A1 (en) 2009-04-16
CN101795703B (zh) 2015-05-06
EP2180897B1 (en) 2019-05-08
US8338364B2 (en) 2012-12-25
EP2180897A1 (en) 2010-05-05
EP2180897A4 (en) 2015-08-26
US20110293709A1 (en) 2011-12-01
CA2728140C (en) 2019-09-03
CN103864892A (zh) 2014-06-18
KR20100039861A (ko) 2010-04-16
JP5568008B2 (ja) 2014-08-06
JP2010531892A (ja) 2010-09-30
WO2009003037A1 (en) 2008-12-31
US8026208B2 (en) 2011-09-27
JP2014193163A (ja) 2014-10-09

Similar Documents

Publication Publication Date Title
KR101507188B1 (ko) 펩티드 티로시나제 억제제 및 그의 용도
KR101561709B1 (ko) 올리고펩티드 티로시나제 억제제 및 그의 용도
CN103096980B (zh) 皮肤抗衰老治疗
US9567368B2 (en) Peptide tyrosinase activators
ES2578636T3 (es) Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene
US9320698B2 (en) Peptide tyrosinase inhibitors and uses thereof
US20060293227A1 (en) Cosmetic compositions and methods using transforming growth factor-beta mimics
US20070154437A1 (en) Peptide-tagged proteins and methods of making and using thereof
HK1191957A1 (zh) 是蛋白trf2调节剂的新型肽和包含其的组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190325

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190325